Although SF3B1 mutations are associated with favorable outcome in MDS6,18, U2AF1 mutations19 give significant adverse risk and poor prognosis.6,15SRSF2 mutations are less frequent but cooccur with additional gene mutations to cause shorter overall survival in MDS.15 Despite the different prognosis in patient outcomes, targeting these mutant splicing factors offers a new therapeutic strategy to treat patients with hematological malignancies.20,21. The gene discussed is U2AF1; the disease is myelodysplastic syndrome.